Min Lu, MD
Medical Oncology · Stanford, CANPI 1568488526
Payments from drug & device makers
Across 144 payments — averaging $12,359 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$996K
- Pfizer$228K
- Radius Health, Inc.$186K
- Genentech, Inc.$136K
- Stemline Therapeutics Inc.$72K
- Merck$65K
- plus $97K from 15 others
Across 17 payments — averaging $424.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
- Radius Health, Inc.$1K
- Pfizer$1K
- Eli Lilly$305
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $995,750 |
| Pfizer | 19 | $228,473 |
| Radius Health, Inc. | 18 | $186,470 |
| Genentech, Inc. | 12 | $135,527 |
| Stemline Therapeutics Inc. | 6 | $72,225 |
| Merck | 29 | $64,574 |
| AstraZeneca | 14 | $60,118 |
| AbbVie | 1 | $14,176 |
| Daiichi Sankyo Inc. | 6 | $4,865 |
| Eli Lilly | 4 | $4,761 |
| Astrazeneca UK Limited | 3 | $4,750 |
| Genentech USA, Inc. | 7 | $3,468 |
| Sanofi | 1 | $2,500 |
| Seagen Inc. | 2 | $1,535 |
| Gilead | 3 | $261 |
| Taiho Oncology, Inc. | 1 | $118 |
| Puma Biotechnology, Inc. | 2 | $65 |
| Incyte Corporation | 1 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| Dova Pharmaceuticals | 1 | $22 |
| Emmaus Medical, Inc. | 1 | $19 |
How this compares
$1,779,728 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Sandhya SrinivasStanford$10.3M
- Melinda TelliStanford$10.3M
- Ranjana AdvaniStanford$7.6M
- Joel NealStanford$6.3M
- Lipika GoyalStanford$5.4M
- Kristen GanjooStanford$4.8M
- Gabriel MannisStanford$3.6M
- Saad Munib Ahmed KhanStanford$3M
- George SledgeStanford$2.1M
- Heather WakeleeStanford$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.